- Home
- GDRX
GDRX
GoodRx Holdings Inc.
as 07-26-2024 4:00pm EST
GoodRx Holdings Inc is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and provides access to negotiated prices through codes that can be used to save money on prescriptions across the United States. GoodRx generates revenue from core business from pharmacy benefit managers (PBMs) that manage formularies and prescription transactions including establishing pricing between consumers and pharmacies. It also offers various healthcare products and services, including pharma manufacturer solutions, subscriptions, and telehealth services.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | SANTA MONICA |
| Market Cap: | 3.2B | IPO Year: | 2020 |
| Target Price: | $9.18 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Buy | Number of Analysts: | 20 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.01 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.14 - $9.37 | Next Earning Date: | 08-08-2024 |
| Revenue: | $764,159,000 | Revenue Growth: | 2.27% |
| Revenue Growth (this year): | 9.65% | Revenue Growth (next year): | 9.43% |
Stock Insider Trading Activity of GoodRx Holdings Inc. (GDRX)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Wagner Scott | GDRX | See Remarks | Nov 30 '23 | Buy | $5.76 | 21,652 | $124,806.46 | 182,900 | SEC Form 4 |
| Wagner Scott | GDRX | See Remarks | Nov 28 '23 | Buy | $6.00 | 4,157 | $24,940.34 | 134,900 | SEC Form 4 |
| Wagner Scott | GDRX | See Remarks | Nov 28 '23 | Buy | $5.90 | 26,348 | $155,482.18 | 161,248 | SEC Form 4 |
| Wagner Scott | GDRX | See Remarks | Nov 16 '23 | Buy | $5.16 | 104,079 | $537,203.76 | 104,079 | SEC Form 4 |
| Wagner Scott | GDRX | See Remarks | Nov 16 '23 | Buy | $5.26 | 26,664 | $140,271.30 | 130,743 | SEC Form 4 |
Latest GoodRx Holdings Inc. News
GDRX Breaking Stock News: Dive into GDRX Ticker-Specific Updates for Smart Investing
Pharmaceutical Technology
7 days ago
Boehringer Ingelheim offers Humira biosimilar at 92% discount
MT Newswires
9 days ago
GoodRx Partners With Boehringer to Offer Discounts for Humira Biosimilar
Yahoo Finance
9 days ago
GoodRx partners with Boehringer Ingelheim to discount Humira biosimilar
PR Newswire
9 days ago
Boehringer Ingelheim and GoodRx announce exclusive patient affordability initiative for Adalimumab-adbm injection, Boehringer's biosimilar to Humira®
MT Newswires
9 days ago
GoodRx's Monthly Active Consumers Likely to be Q2 Results Focus, RBC Says
Zacks
9 days ago
ICLR vs. GDRX: Which Stock Is the Better Value Option?
Business Wire
15 days ago
GoodRx Announces Date for Second Quarter 2024 Earnings Release and Conference Call
Business Wire
16 days ago
Ian T. Clark Joins GoodRx Board of Directors
Compare GDRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GDRX GoodRx Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.